How Kanabo will gain from its smashing debut at London Stock Exchange

  • February 17, 2021 12:11 PM GMT
  • Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1706 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

How Kanabo will gain from its smashing debut at London Stock Exchange

Summary

  • Kanabo came up with an IPO on 16 February which was worth 4.75 pence per share.
  • The shares quadrupled in value at the closing of the first day of trading.

Medical marijuana firm Kanabo, also called Nespresso, saw its shares go up by almost four times in value on its first day of trading on the London Stock Exchange on 16 February with more and more investors getting keen on the new, fast moving cannabis market.  

The shares of the medicinal marijuana company rose more than 292 per cent and closed at 18.5 pence on Tuesday. The IPO of Kanabo’s shares was launched at 4.75 pence, which touched 20.5 pence earlier on Tuesday.  

Having a market capitalization of just over £23 million, the company raised £6 million from share placing. The proceeds from the IPO will be used to fund the marketing and sales, research and development, and clinical trials into using cannabis to treat insomnia.  

Copyright © 2021 Kalkine Media Pty Ltd.

The Israel-based company is engaged in making a medical-grade vapourised marijuana pods, using cartridges of liquid derived from cannabis flowers. Avihu Tamir, Kanabo CEO, said the management was proud and happy to be listed on the LSE. The company could have secured at least £11 million in investment but had to stop sooner, he added.  

Tamir said that Kanabo shared the same enthusiasm as shown by the UK investors on the first day of listing and the reaction received since the prospectus was disclosed two weeks ago has been overwhelming.  

The growing popularity and demand for medical cannabis to treat mental health conditions such as depression, has prompted some countries in Europe to make changes in their listing rules. The legal cannabis market worldwide is worth around $17.5 billion, which is projected to grow to $65 billion by 2027. 

Like North America, the UK and other European markets are all set to witness the medical cannabis industry take off, along with FCA and LSE’s support, Tamir added.  

The Financial Conduct Authority permitted the UK-based cannabis firms to list in London in September 2020 if they agreed to produce it only for medicinal purposes. In 2018, in the UK legalised the medical pot, while recreational use remains illegal. 

The growing acceptance of medical marijuana and weed being legalised for recreational use in North America and other countries, Cannabis has become one of the hottest investment markets in the world.   

Recent listings of medicinal cannabis producing companies 

Last week on 9 February, MGC Pharmaceuticals of Australia (ASX: MXC), the dual-listed pharmaceutical company involved in manufacturing medicinal products out of cannabis plants, saw its shares grow more than three time on its debut on the LSE.  

The stock price of MGC Pharmaceuticals soared to 4.25 pence per share from 1.475 pence per share on the market opening, raising a capital of £75 million. 

Similarly, many other cannabis-based companies are trying to list itself on LSE. David Beckham-backed Cellular Goods, which is a provider of cannabis-based consumer products, has recently said that it would debut on the LSE soon. 

 


Disclaimer
The website https://kalkinemedia.com/uk is a service of Kalkine Media Ltd (Kalkine Media), Company Number 12643132. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK